Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Karolinska Development stock price, quote, forecast and news

KDEV.ST
SE0002190926
A0M84G

Price

1.23
Today +/-
+0.00
Today %
+0.65 %
P

Karolinska Development stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Karolinska Development stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Karolinska Development stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Karolinska Development stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Karolinska Development's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Karolinska Development Stock Price History

DateKarolinska Development Price
9/13/20241.23 undefined
9/12/20241.23 undefined
9/11/20241.20 undefined
9/10/20241.18 undefined
9/9/20241.22 undefined
9/6/20241.22 undefined
9/5/20241.22 undefined
9/4/20241.25 undefined
9/3/20241.25 undefined
9/2/20241.30 undefined
8/30/20241.32 undefined
8/29/20241.37 undefined
8/28/20241.30 undefined
8/27/20241.35 undefined
8/26/20241.36 undefined
8/23/20241.36 undefined
8/22/20241.39 undefined
8/21/20241.40 undefined
8/20/20241.37 undefined
8/19/20241.40 undefined

Karolinska Development Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Karolinska Development, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Karolinska Development from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Karolinska Development’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Karolinska Development. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Karolinska Development’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Karolinska Development’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Karolinska Development’s growth potential.

Karolinska Development Revenue, EBIT and net profit per share

DateKarolinska Development RevenueKarolinska Development EBITKarolinska Development Net Income
2026e2.04 M undefined-30.6 M undefined-16.36 M undefined
2025e2.04 M undefined-29.58 M undefined-27.26 M undefined
2024e2.04 M undefined-23.46 M undefined-27.26 M undefined
20232.01 M undefined-18.69 M undefined5.39 M undefined
20222.3 M undefined-11.34 M undefined-88.12 M undefined
20212.17 M undefined-62.5 M undefined170.82 M undefined
20202.65 M undefined12.95 M undefined-207.49 M undefined
20193.38 M undefined-67.2 M undefined302.98 M undefined
20183.07 M undefined15.54 M undefined30.51 M undefined
20172.46 M undefined-31.56 M undefined179.6 M undefined
20165.36 M undefined-27.51 M undefined-216.83 M undefined
20152.94 M undefined-43.8 M undefined-1.05 B undefined
20145.03 M undefined-63.56 M undefined-371.49 M undefined
20134.95 M undefined-58.75 M undefined-157.32 M undefined
20129.94 M undefined-167.02 M undefined-212.85 M undefined
201110.48 M undefined-156.88 M undefined-354.15 M undefined
201013.9 M undefined-119.47 M undefined-325.62 M undefined
200930.32 M undefined-43.57 M undefined-2.81 M undefined
200823.23 M undefined-41.02 M undefined-57.71 M undefined
200790,000 undefined-6.15 M undefined-6.19 M undefined
20060 undefined-490,000 undefined-480,000 undefined

Karolinska Development Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0023301310945252332222222
---30.43-56.67-23.08-10.00-55.5625.00-60.00150.00-60.0050.00--33.33------
---60.87-30.00-369.23----------------
0-4-14-9-480000000000000000
0-6-41-43-119-156-167-58-63-43-27-3115-6712-62-11-18-23-29-30
---178.26-143.33-915.38-1,560.00-1,855.56-1,450.00-1,260.00-2,150.00-540.00-1,550.00500.00-2,233.33600.00-3,100.00-550.00-900.00-1,150.00-1,450.00-1,500.00
0-6-57-2-325-354-212-157-371-1,054-21617930302-207170-885-27-27-16
--850.00-96.4916,150.008.92-40.11-25.94136.31184.10-79.51-182.87-83.24906.67-168.54-182.13-151.76-105.68-640.00--40.74
33.3333.3333.3333.3333.2643.9148.5348.3548.6153.1560.0969.2272.4383.42198.1198.1257.42269.83000
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The Karolinska Development Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Karolinska Development is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
200620072008200920102011201220132014201520162017201820192020202120222023
                                   
3.436.2310.7515.5243.9620.6282.8200.7141.33297.24248.15169.63138.85114.75117.0592.4205.7995.66
006.83.90.71.50.11.21.190.290.310.250.210.250.270.310.30
5.7360.330.192.88.733.549.540.891.143.911.111.091.270.880
000000000000000000
013.10.91.58.41.92.50.211.170.610.50.420.430.530.672.630.450.8
9.152.3378.7551345.8632.7288.4205.6157.69307.68249.84171.44143.39116.63119.0796.62207.4296.45
00.13.12.62.51.700.50.530.110000.70.690.690.693.16
00.011.281.481.2511.841.771.150.310.190.490.651.050.770.951.041.16
000003.712.95.912.060.910.963.445.11.77061.800
0000179.8703000000000000
001.71.200000000000000
02.60000000000000000
00.021.291.491.431.711.851.771.160.310.190.490.651.050.771.011.041.16
0.010.071.662.041.772.352.141.981.320.610.440.660.791.170.891.111.251.26
                                   
0.10.513.516.616.724.324.324.326.6926.7326.730.640.641.761.761.762.72.7
000.851.21.211.771.771.771.831.871.871.971.972.382.382.382.742.74
-0.5-1.1782.9780.1454.586.4323.1165.2-598.72-1,653.08-1,871.15-1,704.28-1,675.39-1,372.4-1,579.86-1,409.04-1,497.17-1,491.78
0.010.04000000000001.010.8000
000000000000000000
0.010.051.6521.681.882.121.961.260.250.030.270.32.021.60.971.241.25
010.36.2273.19.62.52.44.671.441.461.161.3711.480.621.670.441.32
0.11.13.76.98.9146.58.124.155.556.859.366.456.965.537.278.176.37
0.10.13.36.38.22.8221.474.940.961.630.8349.847.13.910.850.8
000000000000507075.86124.600
000000000000428.320.690.710.730.753.07
0.211.513.240.220.226.41112.530.2811.939.2712.15486.95158.9789.82138.1910.2111.57
0000220022.86349.21394.44379.18000000
000034.2143.6000000000000
3.310000010.99.411.695.444.84.8111.4200-237.100
3.3100036.2145.610.99.434.54354.64399.24383.9911.4200-237.100
3.521.513.240.256.417221.921.964.82366.58408.51396.14498.38158.9789.82-98.9110.2111.57
0.010.071.662.041.742.052.141.981.320.610.440.660.792.171.690.871.251.26
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Karolinska Development provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Karolinska Development's financial health and stability.

Assets

Karolinska Development's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Karolinska Development must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Karolinska Development after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Karolinska Development's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200620072008200920102011201220132014201520162017201820192020202120222023
0-6-70-13-345-400-253-198-367-1,020-17422074347-202160-87-3
0001273500000000000
000000000000000000
-50208-513-609-10-15534130-344-10
0030-3022525096118269710159-254-102-386172-18955-21
00000000000001,0000000
000000000000000000
-6-4-18-34-97-133-212-70-108-325-8-3113-7-3316-32-25
00-20-3-2-700000000000
0-13-4371-181-430164000042-165757-49-113-19
0-12-4352-178-427171000042-165757-49-113-19
000000000000000000
36000000223640-2000000
009242119608-2-2000000002540
950351416-66191-2853310-20-13002350
644258-4-2611300-32000-1300-190
000000000000000000
332-104384-28656-46-73-226-88-33623-3388-45
-6-5.07-20.61-34.69-101.13-136.27-219.43-70.87-108.39-325.02-8.99-31.2113.15-7.41-33.216.7-32.53-25.02
000000000000000000

Karolinska Development stock margins

The Karolinska Development margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Karolinska Development. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Karolinska Development.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Karolinska Development's sales revenue. A higher gross margin percentage indicates that the Karolinska Development retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Karolinska Development's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Karolinska Development's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Karolinska Development's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Karolinska Development. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Karolinska Development's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Karolinska Development Margin History

Karolinska Development Gross marginKarolinska Development Profit marginKarolinska Development EBIT marginKarolinska Development Profit margin
2026e-350.07 %-1,500 %-801.83 %
2025e-350.07 %-1,450 %-1,336.39 %
2024e-350.07 %-1,150 %-1,336.39 %
2023-350.07 %-928 %267.43 %
2022-350.07 %-492.96 %-3,831.39 %
2021-350.07 %-2,880.32 %7,871.84 %
2020-350.07 %488.57 %-7,826.75 %
2019-350.07 %-1,985.67 %8,953.22 %
2018-350.07 %505.82 %992.84 %
2017-350.07 %-1,280.93 %7,288.76 %
2016-350.07 %-513.15 %-4,045.37 %
2015-350.07 %-1,488.78 %-35,848.84 %
2014-350.07 %-1,263.66 %-7,385.45 %
2013-350.07 %-1,186.87 %-3,178.18 %
2012-350.07 %-1,680.28 %-2,141.35 %
2011-350.07 %-1,496.95 %-3,379.29 %
2010-350.07 %-859.5 %-2,342.59 %
2009-29.98 %-143.7 %-9.27 %
2008-63.62 %-176.58 %-248.43 %
2007-4,966.67 %-6,833.33 %-6,877.78 %
2006-350.07 %0 %0 %

Karolinska Development Stock Sales Revenue, EBIT, Earnings per Share

The Karolinska Development earnings per share therefore indicates how much revenue Karolinska Development has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Karolinska Development earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Karolinska Development's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Karolinska Development’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Karolinska Development's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Karolinska Development Revenue, EBIT and net profit per share

DateKarolinska Development Sales per ShareKarolinska Development EBIT per shareKarolinska Development Earnings per Share
2026e0.01 undefined0 undefined-0.06 undefined
2025e0.01 undefined0 undefined-0.1 undefined
2024e0.01 undefined0 undefined-0.1 undefined
20230.01 undefined-0.07 undefined0.02 undefined
20220.01 undefined-0.04 undefined-0.34 undefined
20210.01 undefined-0.32 undefined0.86 undefined
20200.01 undefined0.07 undefined-1.05 undefined
20190.04 undefined-0.81 undefined3.63 undefined
20180.04 undefined0.21 undefined0.42 undefined
20170.04 undefined-0.46 undefined2.59 undefined
20160.09 undefined-0.46 undefined-3.61 undefined
20150.06 undefined-0.82 undefined-19.84 undefined
20140.1 undefined-1.31 undefined-7.64 undefined
20130.1 undefined-1.22 undefined-3.25 undefined
20120.2 undefined-3.44 undefined-4.39 undefined
20110.24 undefined-3.57 undefined-8.07 undefined
20100.42 undefined-3.59 undefined-9.79 undefined
20090.91 undefined-1.31 undefined-0.08 undefined
20080.7 undefined-1.23 undefined-1.73 undefined
20070 undefined-0.18 undefined-0.19 undefined
20060 undefined-0.01 undefined-0.01 undefined

Karolinska Development business model

Karolinska Development AB is a Swedish investment company focused on promoting innovative biotech companies and start-ups. The company was founded in 2003 by the government of the Stockholm region and Karolinska Institutet University. The business model of Karolinska Development is designed to make profitable investments in promising biotech companies. It specifically supports companies in the areas of cancer treatment, immunotherapy, cardiovascular diseases, as well as neurology and psychiatry. The company provides capital and expertise to turn promising innovations into successful products. Karolinska Development operates different divisions to fulfill this purpose, including Karolinska Development AB (parent company), Karolinska Development Life Science Venture AB (a specialized investment company), and Karolinska Development Management AB (portfolio management team). Karolinska Development has built a strong portfolio of companies developing innovative products and therapies. One example is Modus Therapeutics AB, which has developed a new therapy for the treatment of sickle cell anemia. Another example is Aprea AB, a developer of gene therapies for combating cancer using tumor cells and genetic sequencing. The company's history is marked by many successful investments and acquisitions. One example is the acquisition of BioChromix AB in 2012, which developed a new technology for rapid and precise diagnosis of infectious diseases. Karolinska Development also actively participates in supporting new start-ups and company formations to promote promising innovations. Karolinska Development AB plays an important role in the biotech industry and significantly supports research in drug development. Through its unique position as an investor and partner for innovative companies, Karolinska Development is a driving force in the field of biotechnology. The company's business field is characterized by high risk and requires strategic thinking and skillful maneuvering in the market. However, Karolinska Development has managed to build a solid foundation and establish itself as an important player in the biotech industry through targeted investments, acquisitions, and partnerships. In summary, Karolinska Development plays a vital role in the biotech industry in Sweden and worldwide. The company has produced many innovative companies and products through targeted investments and acquisitions, contributing to changing lives and combating diseases. With its unique position as an investor and partner for biotech companies, Karolinska Development is well-equipped to continue promoting new innovations and advancing drug development in the future. Karolinska Development is one of the most popular companies on Eulerpool.com.

Karolinska Development SWOT Analysis

Strengths

Karolinska Development AB has a strong portfolio of innovative life science companies, including a number of promising start-ups.

The company benefits from its close relationship with Karolinska Institutet, one of the world's leading medical universities, which provides access to top-tier scientific research and expertise.

Karolinska Development has a proven track record in identifying and nurturing promising life science innovations, helping them to achieve commercial success.

Weaknesses

The company heavily relies on external funding to support its operations, which exposes it to potential financial risks and uncertainties.

Karolinska Development faces intense competition in the life science industry, with many other venture capital firms and investors targeting similar start-ups and innovations.

There is a possibility of inherent risks associated with the development and commercialization of life science technologies, which may impact the success of Karolinska Development's portfolio companies.

Opportunities

The increasing demand for innovative healthcare solutions presents a significant opportunity for Karolinska Development to further grow its portfolio and generate substantial returns.

The advancements in technology and research provide a favorable environment for the development of new life science breakthroughs, which can be capitalized on by Karolinska Development.

Global trends towards personalized medicine and precision healthcare open up new avenues for investment and collaboration in the life science sector, which Karolinska Development can explore.

Threats

The regulatory landscape for the life science industry is complex and subject to changes, which can pose challenges in terms of compliance and market access for Karolinska Development's portfolio companies.

Market uncertainties and economic fluctuations can impact the funding environment for start-ups and early-stage companies, affecting Karolinska Development's ability to secure necessary investments.

The potential emergence of disruptive technologies or competing solutions may undermine the value and market potential of Karolinska Development's current portfolio.

Karolinska Development Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Karolinska Development historical P/E ratio, EBIT, and P/S ratio.

Karolinska Development shares outstanding

The number of shares was Karolinska Development in 2023 — This indicates how many shares 269.833 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Karolinska Development earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Karolinska Development's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Karolinska Development’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Karolinska Development's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Karolinska Development.

Eulerpool ESG Scorecard© for the Karolinska Development stock

Eulerpool World ESG Rating (EESG©)

17/ 100

🌱 Environment

19

👫 Social

11

🏛️ Governance

19

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees50
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Karolinska Development list of shareholders

%
Name
Stocks
Change
Date
48.16578 % Invox Pharma Limited128,736,38403/31/2023
3.27375 % Swedbank Robur Fonder AB8,750,00003/31/2023
10.47864 % Worldwide International Investments Limited28,007,07703/31/2023
1.73573 % Avanza Bank Holding AB4,639,2144,639,2143/31/2023
0.96529 % Nyenburgh Holding BV2,580,00009/30/2022
0.92433 % Coastal Investment Management, L.P.2,470,54103/31/2023
0.82452 % Östersjöstiftelsen2,203,746-1,685,42012/31/2022
0.66375 % SEB Investment Management AB1,774,062111,9933/31/2023
0.65693 % Stift För Främjande & Utveckling1,755,81803/31/2023
0.56124 % Handelsbanken Kapitalförvaltning AB1,500,08103/31/2024
1
2

Karolinska Development Executives and Management Board

Dr. Viktor Drvota58
Karolinska Development Chief Executive Officer (since 2016)
Compensation 5.56 M
Dr. Bjorn Cochlovius55
Karolinska Development Independent Chairman of the Board
Compensation 400,000
Mr. Benjamin Toogood47
Karolinska Development Director
Compensation 200,000
Ms. Anna Skjoldebrand54
Karolinska Development Independent Director
Compensation 200,000
Mr. Philip Duong33
Karolinska Development Director
Compensation 114,000
1
2
3

Most common questions regarding Karolinska Development

What values and corporate philosophy does Karolinska Development represent?

Karolinska Development AB represents a value-driven corporate philosophy focused on enabling the commercialization of innovative life science technologies. The company is dedicated to improving human health and actively supports the development of breakthrough therapies and medical innovations. Karolinska Development AB strives for long-term financial success while prioritizing ethical and sustainable practices. By identifying promising projects and providing strategic guidance, funding, and industry expertise, the company accelerates the growth of healthcare companies and fosters collaborations within the life science sector. Karolinska Development AB's commitment to driving scientific advancements and delivering shareholder value positions it as a leading player in the industry.

In which countries and regions is Karolinska Development primarily present?

Karolinska Development AB, a renowned Swedish life science investment company, primarily operates in Sweden. With its headquarters situated in Stockholm, the company focuses on identifying and developing innovations within the healthcare sector. Karolinska Development AB plays a crucial role in supporting the commercialization and growth of early-stage life science companies originating from Sweden's prestigious Karolinska Institutet. With an extensive network of contacts and partnerships, Karolinska Development AB drives advancements in the field of biomedicine, primarily within Sweden's vibrant life science ecosystem.

What significant milestones has the company Karolinska Development achieved?

Karolinska Development AB, a leading Nordic life science investment company, has achieved several significant milestones. The company has successfully supported the growth of numerous innovative healthcare companies and fostered collaborations with top academic institutions. Karolinska Development has enabled the development and commercialization of several breakthrough therapies and medical technologies, addressing critical unmet medical needs. Its extensive portfolio encompasses companies focusing on various therapeutic areas, including oncology, rare diseases, and regenerative medicine. With its strategic investments and valuable expertise, Karolinska Development continues to play a vital role in advancing the life sciences industry and improving patient outcomes.

What is the history and background of the company Karolinska Development?

Karolinska Development AB is a leading investment company in the field of life sciences. Established in 2003, the company focuses on identifying and developing innovative pharmaceutical products and medical technologies. As a subsidiary of Karolinska Institutet Holding AB, Karolinska Development collaborates with academia, top-notch experts, and industry stakeholders to bring promising research and commercialize breakthrough innovations. The company's portfolio includes a diverse range of investments in companies involved in drug development, medical devices, diagnostics, and digital health solutions. Karolinska Development aims to leverage its extensive network and knowledge to drive the growth and success of its portfolio companies in the global healthcare market.

Who are the main competitors of Karolinska Development in the market?

The main competitors of Karolinska Development AB in the market include other biotechnology and pharmaceutical companies focusing on innovation and drug development. Some notable competitors include AstraZeneca, Novartis, Pfizer, GlaxoSmithKline, and Johnson & Johnson. These companies compete in the same industry, striving to bring new drugs and therapies to the market. Karolinska Development AB sets itself apart through its expertise in evaluating and identifying promising early-stage life science opportunities.

In which industries is Karolinska Development primarily active?

Karolinska Development AB is primarily active in the life sciences and healthcare industries.

What is the business model of Karolinska Development?

Karolinska Development AB operates as a life sciences investment company. The company's business model focuses on identifying, developing, and commercializing innovative healthcare technologies originating from leading academic research institutions in the Nordic region. Karolinska Development AB aims to support the growth of these projects by providing expertise, funding, and strategic guidance. By actively participating in the development process, the company strives to maximize the potential value of its portfolio of companies. Through partnerships and collaborations, Karolinska Development AB aims to advance medical innovations that address significant unmet medical needs, ultimately benefiting both patients and investors.

What is the P/E ratio of Karolinska Development 2024?

The Karolinska Development P/E ratio is -12.21.

What is the P/S ratio of Karolinska Development 2024?

The Karolinska Development P/S ratio is 163.22.

What is the AlleAktien quality score of Karolinska Development?

The AlleAktien quality score cannot be calculated for Karolinska Development at the moment.

What is the revenue of Karolinska Development 2024?

The expected Karolinska Development revenue is 2.04 M SEK.

How high is the profit of Karolinska Development 2024?

The expected Karolinska Development profit is -27.26 M SEK.

What is the business model of Karolinska Development

Karolinska Development AB specializes in the development of medications and medical technologies. The company's business model is based on building partnerships with promising startups and research institutions in the healthcare sector and supporting them in bringing their products and technologies to market. The company operates in four strategic business areas: company formation, technology development, product development, and management consulting. Karolinska Development AB aims to become a leading company in the healthcare industry and promote the development of medications and medical technologies.

What is the Karolinska Development dividend?

Karolinska Development pays a dividend of 0 SEK distributed over payouts per year.

How often does Karolinska Development pay dividends?

The dividend cannot currently be calculated for Karolinska Development or the company does not pay out a dividend.

What is the Karolinska Development ISIN?

The ISIN of Karolinska Development is SE0002190926.

What is the Karolinska Development WKN?

The WKN of Karolinska Development is A0M84G.

What is the Karolinska Development ticker?

The ticker of Karolinska Development is KDEV.ST.

How much dividend does Karolinska Development pay?

Over the past 12 months, Karolinska Development paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Karolinska Development is expected to pay a dividend of 0 SEK.

What is the dividend yield of Karolinska Development?

The current dividend yield of Karolinska Development is .

When does Karolinska Development pay dividends?

Karolinska Development pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Karolinska Development?

Karolinska Development paid dividends every year for the past 0 years.

What is the dividend of Karolinska Development?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Karolinska Development located?

Karolinska Development is assigned to the 'Health' sector.

Wann musste ich die Aktien von Karolinska Development kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Karolinska Development from 9/16/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 9/16/2024.

When did Karolinska Development pay the last dividend?

The last dividend was paid out on 9/16/2024.

What was the dividend of Karolinska Development in the year 2023?

In the year 2023, Karolinska Development distributed 0 SEK as dividends.

In which currency does Karolinska Development pay out the dividend?

The dividends of Karolinska Development are distributed in SEK.

All fundamentals about Karolinska Development

Our stock analysis for Karolinska Development Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karolinska Development Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.